Letters by company
Hagerty, Inc.
3 letters discussing HGTY. Everything written about it on this site is on its ticker page.
- Greenhaven Road Capital Main Fund Q2 Greenhaven Road Capital is reducing concentration, adding near-term catalysts and taking profits more readily while retaining its focus on advantaged businesses. It argues that Burford’s protein litigation, Hagerty’s insurer partnerships, Cellebrite’s Genesis launch, Lifecore’s strategic process and Kingsway’s search-model buildout can close valuation gaps. second quarter 2026 ANAB $1.4BBUR $772MCLBT $2.9B
- Greenhaven Road Capital Q4 2025 Greenhaven Road Capital groups Lifecore and Vistry as transformations whose operating progress has yet to be reflected in their valuations. It argues that fears around Burford, PAR, Cellebrite and KKR are overstated, while Hagerty’s State Farm rollout, operating leverage and marketplace expansion support its investment case. Q4 2025 BUR $772MCLBT $2.9BHGTY $4.8B
- Greenhaven Road Capital Q1 2025 Greenhaven Road increased Lifecore, Vistry and Hagerty after tariff-related selling, while retaining its core case for KKR, PAR and Cellebrite. It presents Kingsway as an underfollowed acquirer that can scale a search-fund model through operator-led purchases of small, asset-light businesses. Q1 2025 BUR $772MCLBT $2.9BKKR $80B
